Full Year Statutory Accounts
Filed with ASX · · 105 pages · English
Lodged with the ASX under Listing Rule 4.3A. Contents Results for Announcement to the Market Additional Information CSL Limited ###### ABN: 99 051 588 348 ###### Appendix 4E ###### Full-year ended 30 June 2018 ###### (Previous corresponding period: Year ended 30 June 2017) Results for Announcement to the Market Reported • Sales revenue up 14.7% to US$7.6 billion. • Net profit after tax for the yea
Earlier from CSL
- CSL Lifts Profit Guidance
- CEOs AGM Presentation
- New Debt Facilities
- FDA Approves Privigen for CIDP Indication
- CSL Behring Acquires US Biotech Company Calimmune
Later from CSL
- Full Year Results Announcement
- CSL R&D Investor Briefing
- Appendix 4D and Half Year Accounts
- Half Year Results Analyst Presentation
- Update on CSL transition to own distributor model in China
Follow CSL into a list and get an email when it puts out news.
Follow CSL